Table 1 |
|
|
Cohort characteristics at baseline |
|
|
Characteristic |
Baseline value |
|
|
|
|
Gender Female Male |
(N = 9040) 5962 (66) 3078 (34) |
|
|
|
|
Age (years) < 25 years 25-34 years 35-44 years 45-54 years > 55 years |
(N = 9040) 551 (6.1) 3822 (42.3) 3216 (35.5) 1173 (13.0) 277 (3.1) |
|
|
|
|
WHO AIDS classification Stage 1 Stage 2 Stage 3 Stage 4 |
(N = 8714) 4086 (46.9) 1310 (15) 2507 (28.8) 811 (9.3) |
|
|
|
|
HAART d4T/3TC/EFV d4T/3TC/NVP d4T/3TC/Kaletra AZT containing regimen TDF containing regimen other |
(N = 9040) 7138 (79) 690 (7.6) 669 (7.4) 308 (3.4) 59 (0.7) 176 (1.9) |
|
|
|
|
BMI (kg/m2) |
22.4 ± 5.0 (N = 7010) |
|
|
|
|
CD4 count (cells/mm3) |
81 (29-149) (N = 7605) |
|
|
|
|
Follow up time on HAART (months) |
19.0 (9.1-31.6) (N = 9040) |
|
|
|
|
Data is expressed as N (%) except for BMI (mean ± SD), CD4 count (median, IQR) and follow up time on HAART (median, IQR). WHO, World Health Organization, d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; kaletra, ritonavir/lopinavir; AZT, zidovudine; TDF, tenofovir. |
|
|
Menezes et al. BMC Infectious Diseases 2011 11:244 doi:10.1186/1471-2334-11-244 |
|
